Cancer

Three leading lights in the neuro-oncology sphere explain what inspired them, how the field has evolved, and what challenges lie ahead.

New evidence suggests there’s more to metastasis than MMPs, demanding a therapeutic rethink.

We should be thrilled with the success of the approved CD-19 CAR-T therapies. But the field is still young, and we are only scratching the surface.

Higher tumor mutational burden is linked to improved survival across multiple cancer types.

We don’t fully understand how probiotics affect cancer patient prognosis, so they should be approached with caution – at least for now.

How a 3D-printed chemical absorber could pave the way for higher chemotherapy doses – or lower risks.

Sitting Down With… Ingun Holen, Professor of Bone Oncology at the University of Sheffield Medical School, Sheffield, UK.

The role of different types of MET mutation in lung cancer could demand a rethink of treatments.

“Right to Try” legislation may have compassion at its heart, but it does not do enough to ensure patient protection.

Looking at miRNA expression levels may improve our ability to subtype bladder cancers and provide the most appropriate and effective treatment